keyword
MENU ▼
Read by QxMD icon Read
search

Uric acid and ckd and rct

keyword
https://www.readbyqxmd.com/read/27903994/synbiotic-supplementations-for-azotemia-in-patients-with-chronic-kidney-disease-a-randomized-controlled-trial
#1
Hamideh Dehghani, Fatemeh Heidari, Hassan Mozaffari-Khosravi, Nader Nouri-Majelan, Ali Dehghani
INTRODUCTION: Chronic kidney disease (CKD) is a progressive and irreversible impairment of kidney function; if it progresses to the end-stage of CKD, dialysis or kidney transplant is needed. In general, there are no definitive treatment to slow the progression of CKD. This study aimed to determine the effect of synbiotic supplementations on azotemia in patients with CKD. MATERIALS AND METHODS: A randomized controlled trial was conducted on 66 patients with CKD (stages 3 and 4)...
November 2016: Iranian Journal of Kidney Diseases
https://www.readbyqxmd.com/read/27696189/hyperuricemia-hypertension-and-chronic-kidney-disease-an-emerging-association
#2
Samir G Mallat, Sahar Al Kattar, Bassem Y Tanios, Abdo Jurjus
Uric acid is a product of purine metabolism and has been linked to gout and kidney calculi. Chronic kidney disease (CKD) and hypertension (HTN) are two major public health problems, and both are associated with increased risk of cardiovascular events. Emerging evidence suggests a pathogenic role of hyperuricemia in the development of HTN and CKD, in addition to progression of CKD, by inducing renal inflammation, endothelial dysfunction, and activation of the renin-angiotensin system. In addition, several epidemiological studies have linked hyperuricemia with an increased risk of HTN and CKD...
October 2016: Current Hypertension Reports
https://www.readbyqxmd.com/read/27506740/serum-uric-acid-and-mortality-in-chronic-kidney-disease-a-systematic-review-and-meta-analysis
#3
Xi Xia, Qimei Luo, Bin Li, Zhenchuan Lin, Xueqing Yu, Fengxian Huang
BACKGROUND: Studies have shown inconsistent results about the association between serum uric acid levels and mortality in patients with chronic kidney disease (CKD). METHODS: A systematic literature search in MEDLINE, Web of Science and bibliographies of retrieved articles was performed to identify studies investigating the association between serum uric acid and mortality in patients with CKD. Pooled hazard ratios (HR) and corresponding 95% confidence intervals (CIs) were calculated using random-effects models...
September 2016: Metabolism: Clinical and Experimental
https://www.readbyqxmd.com/read/27269247/the-budget-impact-of-increased-use-of-febuxostat-in-the-management-of-gout-a-us-health-plan-managed-care-pharmacy-and-medical-costs-perspective
#4
Lee J Smolen, James C Gahn, Ghaith Mitri, Aki Shiozawa
PURPOSE: Gout is a chronic disease characterized by the deposition of urate crystals in the joints and throughout the body, caused by an excess burden of serum uric acid (sUA). The study estimates pharmacy and medical cost budgetary impacts of wider adoption by US payers of febuxostat, a urate-lowering therapy (ULT) for the treatment of gout. METHODS: A US payer-perspective budget impact model followed ULT patients from a 1,000,000-member plan over 3 years. The current market share scenario, febuxostat (6%) and ULT allopurinol (94%), was compared with an 18% febuxostat market share...
July 2016: Clinical Therapeutics
https://www.readbyqxmd.com/read/26535593/febuxostat-in-the-management-of-gout-a-cost-effectiveness-analysis
#5
Lee J Smolen, James C Gahn, Ghaith Mitri, Aki Shiozawa
OBJECTIVE: To determine the cost-effectiveness of febuxostat vs allopurinol for the management of gout. METHODS: A stochastic microsimulation cost-effectiveness model with a US private-payer perspective and 5-year time horizon was developed. Model flow based on guideline and real-world treatment paradigms incorporated gout flare, serum uric acid (sUA) testing, treatment titration, discontinuation, and adverse events, chronic kidney disease (CKD) incidence and progression, and type 2 diabetes mellitus (T2DM) incidence...
2016: Journal of Medical Economics
https://www.readbyqxmd.com/read/25928556/urate-lowering-therapy-to-improve-renal-outcomes-in-patients-with-chronic-kidney-disease-systematic-review-and-meta-analysis
#6
REVIEW
Tahir Kanji, Mandark Gandhi, Catherine M Clase, Robert Yang
BACKGROUND: Hyperuricemia may contribute to renal injury. We do not know whether use of treatments that lower urate reduce the progression of chronic kidney disease (CKD) and cardiovascular disease. We performed a systematic review and meta-analysis of randomized controlled trials to assess the benefits and risks of treatments that lower urate in patients with stages 3-5 CKD. METHODS: We searched MEDLINE, EMBASE, CENTRAL, Web of Science and trial registers for randomized controlled trials (RCTs) without language restriction...
2015: BMC Nephrology
https://www.readbyqxmd.com/read/25676011/renoprotective-effects-of-febuxostat-in-hyperuricemic-patients-with-chronic-kidney-disease-a-parallel-group-randomized-controlled-trial
#7
RANDOMIZED CONTROLLED TRIAL
Kenichi Tanaka, Masaaki Nakayama, Makoto Kanno, Hiroshi Kimura, Kimio Watanabe, Yoshihiro Tani, Yoshimitsu Hayashi, Koichi Asahi, Hiroyuki Terawaki, Tsuyoshi Watanabe
BACKGROUND: Hyperuricemia is associated with the onset of chronic kidney disease (CKD) and renal disease progression. Febuxostat, a novel, non-purine, selective xanthine oxidase inhibitor, has been reported to have a stronger effect on hyperuricemia than conventional therapy with allopurinol. However, few data are available regarding the clinical effect of febuxostat in patients with CKD. METHODS: A prospective, randomized, open-label, parallel-group trial was conducted in hyperuricemic patients with stage 3 CKD...
December 2015: Clinical and Experimental Nephrology
https://www.readbyqxmd.com/read/25595565/allopurinol-and-progression-of-ckd-and-cardiovascular-events-long-term-follow-up-of-a-randomized-clinical-trial
#8
RANDOMIZED CONTROLLED TRIAL
Marian Goicoechea, Soledad Garcia de Vinuesa, Ursula Verdalles, Eduardo Verde, Nicolas Macias, Alba Santos, Ana Pérez de Jose, Santiago Cedeño, Tania Linares, Jose Luño
BACKGROUND: Asymptomatic hyperuricemia increases renal and cardiovascular (CV) risk. We previously conducted a 2-year, single-blind, randomized, controlled trial of allopurinol treatment that showed improved estimated glomerular filtration rate and reduced CV risk. STUDY DESIGN: Post hoc analysis of a long-term follow-up after completion of the 2-year trial. SETTING & PARTICIPANTS: 113 participants (57 in the allopurinol group and 56 in the control group) initially followed up for 2 years and 107 participants followed up to 5 additional years...
April 2015: American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation
https://www.readbyqxmd.com/read/25367171/antihypertensive-effectiveness-of-combination-therapy-with-losartan-hydrochlorothiazide-for-real-world-management-of-isolated-systolic-hypertension
#9
Hiromichi Suzuki, Kazuyuki Shimada, Kenji Fujiwara
OBJECTIVES: The guidelines for hypertension require the presence of compelling indications for pharmacological management of hypertension associated with various diseases. Data mainly obtained through randomized controlled trials have provided evidence supporting effectiveness of the combination of losartan (Lo) and hydrochlorothiazide (HCTZ) for management of hypertensive patients. However, there have been few reports discussing the effectiveness of Lo/HTCZ (losartan 50 mg/hydrochlorothizide 12...
February 2015: Therapeutic Advances in Cardiovascular Disease
https://www.readbyqxmd.com/read/25135714/effect-of-uric-acid-lowering-therapy-on-progression-of-chronic-kidney-disease-a-meta-analysis
#10
REVIEW
Ye-fang Zhang, Fan He, Hong-hui Ding, Wei Dai, Qian Zhang, Hong Luan, Yong-man Lv, Hong-bing Zeng
The efficacy and safety of uric-acid-lowering therapy (UALT) on slowing the progression of chronic kidney disease (CKD) accompanied by hyperuricemia were assessed. We searched Cochrane Library, PubMed, EMbase, CNKI, Wanfang and Vip databases up to November 15, 2012 for randomized controlled trials (RCTs) which compared the effect of UALT to control therapy in hyperuricemic patients secondary to CKD, and then performed quality evaluation and meta-analysis on the included studies. Seven RCTs involving 451 cases were included...
August 2014: Journal of Huazhong University of Science and Technology. Medical Sciences
https://www.readbyqxmd.com/read/24454316/uric-acid-key-ingredient-in-the-recipe-for-cardiorenal-metabolic-syndrome
#11
REVIEW
Kunal Chaudhary, Kunal Malhotra, James Sowers, Annayya Aroor
Elevated serum uric acid levels are a frequent finding in persons with obesity, hypertension, cardiovascular and kidney disease as well as in those with the cardiorenal metabolic syndrome (CRS). The increased consumption of a fructose-rich Western diet has contributed to the increasing incidence of the CRS, obesity and diabetes especially in industrialized populations. There is also increasing evidence that supports a causal role of high dietary fructose driving elevations in uric acid in association with the CRS...
October 2013: Cardiorenal Medicine
https://www.readbyqxmd.com/read/24433285/the-effect-of-febuxostat-to-prevent-a-further-reduction-in-renal-function-of-patients-with-hyperuricemia-who-have-never-had-gout-and-are-complicated-by-chronic-kidney-disease-stage-3-study-protocol-for-a-multicenter-randomized-controlled-study
#12
RANDOMIZED CONTROLLED TRIAL
Tatsuo Hosoya, Kenjiro Kimura, Sadayoshi Itoh, Masaaki Inaba, Shunya Uchida, Yasuhiko Tomino, Hirofumi Makino, Seiichi Matsuo, Tetsuya Yamamoto, Iwao Ohno, Yugo Shibagaki, Satoshi Iimuro, Naohiko Imai, Masanari Kuwabara, Hiroshi Hayakawa
BACKGROUND: Hyperuricemia is a risk factor for the onset of chronic kidney disease (CKD) and is significantly associated with the progression of CKD. However, there is no sufficient evidence by interventional research supporting a cause-effect relationship. Hyperuricemic patients without gouty arthritis, whose serum urate (SUA) concentration is ≥8.0 mg/dL and who have a complication, are treated by pharmacotherapy in addition to lifestyle guidance. Nevertheless, there is no evidence that rationalizes pharmacotherapy for patients with hyperuricemia who have no complication and whose SUA concentration is below 9...
2014: Trials
https://www.readbyqxmd.com/read/24419747/serum-uric-acid-and-the-risk-of-hypertension-and-chronic-kidney-disease
#13
REVIEW
Daniel I Feig
PURPOSE OF REVIEW: To discuss the evolving data regarding uric acid as a potential cause of hypertension and progressive renal dysfunction and its clinical and research implications. RECENT FINDINGS: The potential mechanisms by which uric acid could cause vasoconstriction and a progressive ateriolopathy were established in animal models between 1999 and 2004. Since then, there has been a growing interest in the topic and numerous retrospective and prospective observational studies...
March 2014: Current Opinion in Rheumatology
https://www.readbyqxmd.com/read/24231660/a-within-patient-analysis-for-time-varying-risk-factors-of-ckd-progression
#14
MULTICENTER STUDY
Liang Li, Alexander Chang, Stephen G Rostand, Lee Hebert, Lawrence J Appel, Brad C Astor, Michael S Lipkowitz, Jackson T Wright, Cynthia Kendrick, Xuelei Wang, Tom H Greene
Recent data suggest that nonlinear GFR trajectories are common among patients with CKD, but the modifiable risk factors underlying these changes in CKD progression rate are unknown. Analyses relating baseline risk factors to subsequent GFR decline are suboptimal because these relationships often attenuate as follow-up time increases and these analyses do not account for temporal changes in risk factors. We identified 74 participants in the African American Study of Kidney Disease and Hypertension who had both a period of rapid GFR decline and an extended period of stability during a follow-up period of ≥12 years...
March 2014: Journal of the American Society of Nephrology: JASN
https://www.readbyqxmd.com/read/24042021/effects-of-uric-acid-lowering-therapy-on-renal-outcomes-a-systematic-review-and-meta-analysis
#15
REVIEW
Bhadran Bose, Sunil V Badve, Swapnil S Hiremath, Neil Boudville, Fiona G Brown, Alan Cass, Janak R de Zoysa, Robert G Fassett, Randall Faull, David C Harris, Carmel M Hawley, John Kanellis, Suetonia C Palmer, Vlado Perkovic, Elaine M Pascoe, Gopala K Rangan, Robert J Walker, Giles Walters, David W Johnson
BACKGROUND: Non-randomized studies suggest an association between serum uric acid levels and progression of chronic kidney disease (CKD). The aim of this systematic review is to summarize evidence from randomized controlled trials (RCTs) concerning the benefits and risks of uric acid-lowering therapy on renal outcomes. METHODS: Medline, Excerpta Medical Database and Cochrane Central Register of Controlled Trials were searched with English language restriction for RCTs comparing the effect of uric acid-lowering therapy with placebo/no treatment on renal outcomes...
February 2014: Nephrology, Dialysis, Transplantation
https://www.readbyqxmd.com/read/23869492/enalapril-versus-losartan-for-adults-with-chronic-kidney-disease-a-systematic-review-and-meta-analysis
#16
REVIEW
Yuan-Mei He, Li Feng, Dong-Mei Huo, Zhen-Hua Yang, Yun-Hua Liao
AIM: Both enalapril and losartan are effective and widely used in patients with chronic kidney disease (CKD). This review aimed to evaluate the benefits of enalapril and losartan in adults with CKD. METHODS: PubMed, EMBASE, the Cochrane Library and ClinicalTrials.gov were searched, without language limitations, for randomized controlled trials (RCT), in which enalapril and losartan were compared in adults with CKD. Standard methods, consistent with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, were used...
September 2013: Nephrology
https://www.readbyqxmd.com/read/22960848/management-of-gouty-arthritis-in-patients-with-chronic-kidney-disease
#17
REVIEW
Abdul A Abdellatif, Naser Elkhalili
Chronic kidney disease (CKD) is a comorbid condition that affects, based on recent estimates, between 47% and 54% of patients with gouty arthritis. However, data from randomized controlled trials in patients with gouty arthritis and CKD are limited, and current gouty arthritis treatment guidelines do not address the challenges associated with managing this patient population. Nonsteroidal anti-inflammatory drugs and colchicine are recommended first-line treatments for acute gouty arthritis attacks. However, in patients with CKD, nonsteroidal anti-inflammatory drugs are not recommended because their use can exacerbate or cause acute kidney injury...
November 2014: American Journal of Therapeutics
https://www.readbyqxmd.com/read/22260409/new-insights-into-uric-acid-effects-on-the-progression-and-prognosis-of-chronic-kidney-disease
#18
REVIEW
Vassilis Filiopoulos, Dimitrios Hadjiyannakos, Dimosthenis Vlassopoulos
Hyperuricemia is particularly common in patients with arterial hypertension, metabolic syndrome, or kidney disease. Its role, however, as a risk factor for both renal and cardiovascular outcomes and in the context of the well-established interrelationship between cardiovascular disease and chronic kidney disease (CKD) is debated. For decades high serum uric acid levels were mainly considered the result of renal dysfunction and not a true mediator of renal disease development and progression. However, recent epidemiological studies suggest an independent association between asymptomatic hyperuricemia and increased risk of arterial hypertension, CKD, cardiovascular events, and mortality...
2012: Renal Failure
https://www.readbyqxmd.com/read/21321568/challenges-of-conducting-a-trial-of-uric-acid-lowering-therapy-in-ckd
#19
Sunil V Badve, Fiona Brown, Carmel M Hawley, David W Johnson, John Kanellis, Gopala K Rangan, Vlado Perkovic
Observational studies have shown that asymptomatic hyperuricemia is associated with increased risks of hypertension, chronic kidney disease (CKD), end-stage renal disease, cardiovascular events, and mortality. Whether these factors represent cause, consequence or incidental associations, however, remains uncertain. Hyperuricemia could be a consequence of impaired kidney function, diuretic therapy or oxidative stress, such that elevated serum urate level represents a marker, rather than a cause, of CKD. On the other hand, small, short-term, single-center studies have shown improvements in blood-pressure control and slowing of CKD progression following serum urate lowering with allopurinol...
May 2011: Nature Reviews. Nephrology
https://www.readbyqxmd.com/read/21199831/hyperuricaemia-chronic-kidney-disease-and-outcomes-in-heart-failure-potential-mechanistic-insights-from-epidemiological-data
#20
Gerasimos S Filippatos, Mustafa I Ahmed, James D Gladden, Marjan Mujib, Inmaculada B Aban, Thomas E Love, Paul W Sanders, Bertram Pitt, Stefan D Anker, Ali Ahmed
AIM: To determine if the association between hyperuricaemia and poor outcomes in heart failure (HF) varies by chronic kidney disease (CKD). METHODS AND RESULTS: Of the 2645 systolic HF patients in the Beta-Blocker Evaluation of Survival Trial with data on baseline serum uric acid, 1422 had hyperuricaemia (uric acid ≥6 mg/dL for women and ≥8 mg/dL for men). Propensity scores for hyperuricaemia, estimated for each patient, were used to assemble a matched cohort of 630 pairs of patients with and without hyperuricaemia who were balanced on 75 baseline characteristics...
March 2011: European Heart Journal
keyword
keyword
101042
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"